AGIO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

AGIO ▼ -5.85% at T+5d

SHORT call ✓ call won +5.85% · α vs SPY +5.56% · entry $29.40 → $27.68

Next anchor: T+20d in 23d

Currently $28.29 · +3.78% from $29.40 entry (call sign-flipped)

Entry anchored
May 29, 05:27 AM ET
via Databento tick

T+1d

-4.76%

call +4.76% · α +5.04%

$28.00

settled 5d ago

T+5d

-5.85%

call +5.85% · α +5.56%

$27.68

settled 13h ago

T+20d

—

call — · α —

—

in 23d

T+60d

—

call — · α —

—

in 3mo

Price Chart

Loading chart...

Executive Summary

Agios Pharmaceuticals announced it will not advance tebapivat, its next-generation oral PK activator, in lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b trial failed to meet the predefined threshold for clinical benefit. The decision removes a pipeline opportunity but the company continues to evaluate tebapivat in sickle cell disease with topline data expected in H2 2026.

Actionable Insight

The LR-MDS failure reduces tebapivat's total addressable opportunity but does not affect the sickle cell disease catalyst due H2 2026. Monitor for any further pipeline prioritization updates and the upcoming Phase 2 sickle cell data, which is now the sole near-term catalyst for tebapivat.

Key Facts

Phase 2b trial of tebapivat in LR-MDS did not meet predefined threshold for further development
Tebapivat showed biological activity but insufficient clinical benefit in 65-patient study
No new safety signals were identified; drug was well tolerated
Agios continues Phase 2 trial of tebapivat in sickle cell disease with topline data expected H2 2026
LR-MDS program discontinuation removes a potential pipeline catalyst

Financial Impact

Pipeline setback with no disclosed financial impact; R&D costs for LR-MDS program are sunk. Sickle cell disease program remains the key value driver.

pipeline valueR&D expenditure

Risk Factors

Sickle cell disease Phase 2 trial may also fail to meet endpoints
Competing therapies for sickle cell disease may limit tebapivat's commercial potential
Pipeline concentration risk increases with LR-MDS program discontinued

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

75% bullish (16 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3303496

7 reports for AGIO

T+1T+5T+20T+60

Filters

Reports for AGIO — sortable, filterable
	Type				Now
Jun 1, 2026 4d ago	Press Release MIXED ★ 6/10	—	awaiting T+5	—	—
May 29, 2026 7d ago	Press Release BEARISH ★ 6/10	$29.40 $27.68	▲ +5.85%	▲ +5.56%	$28.29 (+3.78%)
Apr 29, 2026 5w ago	8-K NEUTRAL ★ 5/10	—	awaiting T+5	—	—
Apr 29, 2026 5w ago	Press Release BULLISH ★ 6/10	—	awaiting T+5	—	—
Apr 24, 2026 6w ago	DEFA14A NEUTRAL ★ 2/10	$24.43 $27.56	▲ +12.81%	▲ +12.41%	$28.29 (+15.80%)
Apr 6, 2026 8w ago	Press Release NEUTRAL ★ 3/10	$34.80 $33.15	▼ −4.74%	▼ −8.88%	$28.29 (−18.71%)
Mar 3, 2026 13w ago	Insider Cluster NEUTRAL ★ 3/10	$28.48 $28.26	▼ −0.77%	▼ −0.29%	$28.29 (−0.67%)

US Market Status

Market Closed — Opens Mon (36h 44m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access